Ion Channel Target Research Collaboration With RaQualia Pharma Inc.
First written in FY2022. 4 of 5 entries say "Advanced", first in FY2025. Latest entry: FY2026.
0 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「We will also introduce drug discovery platform technologies targeting ion channels as a new drug discovery platform and challenge unmet medical needs in new areas in addition to our priority areas.」
ラクオリア創薬との共同研究に続き、イオンチャネル創薬基盤技術の導入を新たな創薬プラットフォームとして位置付け、新領域への展開を明示している。 - FY2025AdvancedAnnual report
「We will also introduce drug discovery platform technologies targeting ion channels as a new drug discovery platform and challenge unmet medical needs in new areas in addition to our priority areas.」
ラクオリア創薬との特定イオンチャネル共同研究に加え、イオンチャネル創薬基盤技術の導入による新領域展開を記載している。 - FY2022First statedAnnual report
「In November 2021, we entered into a new joint research agreement with RaQualia Pharma Inc. to create new drugs by leveraging the results obtained to date from our ongoing joint drug discovery research targeting specific ion channels.」
A new joint research agreement with RaQualia Pharma Inc. to create new drugs using existing research results is described as a separate theme for the first time.